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Abstract:  The chemotherapeutic all-trans retinoic acid (ATRA) used in the treatment of 
Acute Promyelocytic Leukemia has adverse effects on its oral administration, with which we 
incorporated a system of drugs, the nanocapsules, in order to have a possible improvement 
in solubility, photosensitivity, lower toxicity, generating pharmacological efficacy. The 
objective was to evaluate and compare the hemolytic and coagulation activity of the 
free drug (AL), nanoencapsulated (NA) and the white nanocapsules (NB) by analyzing the 
results of hemolysis, Prothrombin Time (PT) and Activated Partial Thromboplastin Time 
(APTT). We developed a prospective study of treatments at different concentrations of 
0.25; 0.5; 1.0; 1.5; 2.0; 2.5 μg/mL. For the first test, all concentrations showed hemolytic 
activity, but when compared to NA with ATRA it is observed that these carriers induced 
lower hemolytic toxicity. In the PT test the nanoparticles at the two lowest concentrations 
remained in the physiological range (12 - 15 seconds). For the APTT test the three lowest 
concentrations remained within the control (25 - 35 seconds). Thus, we believe there is a 
promising benefit of using these nanoparticles developed and no doubt further studies 
will be performed to confirm the responses obtained here.
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1 INTRODUCTION
Bleeding is a frequent and potentially lethal complication in cancer patients. It may 
be directly related to the disease, to the antineoplastic treatment or to factors not related 
to the neoplasia itself.1
The control of this alteration in the site of the endothelial lesion includes the action 
of subendothelium, endothelium, platelets and plasma proteins, a process which it is 
called hemostasis.1
One of the clotting disorders severely encountered in the clinical course of many 
pathologies, especially Acute Promyelocytic Leukemia (APL) is Disseminated Intravascular 
Coagulation (DIC). DIC is currently defined as an acquired syndrome, characterized by the 
diffuse activation of intravascular coagulation, leading to the formation and deposition of 
fibrin in the microvasculature.2
The clinical course of APL in recent years has been modified from a rapidly fatal 
acute leukemia to one of the more curable AML subtypes. This revolutionary progress 
in the prognosis of the disease is essentially associated with the remarkable advances in 
its treatment, more specifically with the introduction of new therapeutic agents that act 
directly in the molecular alteration, as is the case of all-trans retinoic acid derived from 
vitamin A (ATRA) and arsenic trioxide (ATO).
After following the administration, a rapid increase in leukocytes is observed, which 
is accompanied by Differentiation Syndrome.3 On the other hand, when administered 
orally, its bioavailability is reduced, and this can be attributed to its low solubility in water. 
Moreover, this type of treatment, when prolonged, provides a progressive reduction of its 
plasma concentration, which can be attributed to its increased metabolism and increased 
haemolytic toxicity.4
To reduce this disadvantage and adverse effect of free ATRA, this work aimed to 
incorporate the ATRA into a different drug delivery system, the nanocapsules, which when 
combined with the drug can improve the solubility, photosensitivity, toxicity, chemical 
stability, bioavailability and/or pharmacological efficacy.5 In addition, the ATRA is a lipophilic 
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drug that is very poorly soluble in water, and its incorporation into lipid nanocarriers is an 
interesting alternative to allow its intravenous administration to replace oral use.6 
Therefore, we used the determination of hemoglobin release in red blood cells as 
an in vitro model, as well as the possible effects on blood coagulation to study the toxicity 
of ATRA, ATRA nanocapsuled and blank nanocapsules.
2 MATERIALS AND METHODS
This work consisted of two stages: the first one to produce and characterize the 
nanocapsule suspensions, and a prospective in vitro study was carried out in which red blood 
cells and plasma were used as an experimental model to investigate the potential hemolytic 
and coagulation effects of the chemotherapeutic ATRA and its nanoencapsulated form.
The discard samples were obtained from healthy donors from peripheral blood, 
from the Laboratory of Clinical Analysis (LEAC) of the Universidad Franciscana under the 
Ethics Committee of the institution and CAAE registry: 31211214.4.0000.5306. 
The samples were collected by venipuncture using Vacutainer tubes (BD Diagnostics, 
Plymouth, UK) containing EDTA (ethylenediaminetetraacetic acid) for hemolysis and 
sodium citrate for coagulation.
The nanoparticles loaded with ATRA (NA) and the blank nanocapsules (NB) - drug-
free in the structure - were produced according to the formulation described by Ourique 
et al.,6 with some adaptations. For the preparation of the nanocapsules, the interfacial 
deposition method of the polymer, described by Fessi, Puisieux, Devissaguet, Ammoury, 
and Benita,7 was used. 
The ATRA content found for the drug loaded nanocapsules was 98% at a 
concentration of 0.5 μg/mL. The treatment for both tests was performed with ATRA, 
nanocapsuled ATRA and blank nanocapsule, in the following concentrations of 0.25; 0.5; 
1.0; 1.5; 2.0; 2.5 μg/mL.
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2.1 HEMOLYTIC ACTIVITY
The methodology followed according to Dobrovolskaia et al.8 Blood was added to 
1x PBS at 1: 1 ratio and centrifuged 15 minutes at 1000 rpm, the supernatant was discarded, 
and this procedure was performed three times. Subsequently, in a new tube containing 1 
mL of 1x PBS, 400 μL of already washed red blood cells and 80 μL of treatment were 
added. As negative control cells were used (400 μL) and PBS 1x (1mL) and as positive 
control cells (400 μL), PBS 1x (1mL) and H2O2 (80 μL). The tubes were incubated in a 37 
°C at 5% CO2 for 1 hour. It was then centrifuged for 5 minutes at 1000 rpm and 100 μL of 
the supernatant to a 96-well plate, which was read in ELISA reader at 405 nm.
2.2 COAGULATION TEST
This assay was performed according to protocol Nanotechnology Characterization 
Laboratory (Frederick National Laboratory for Cancer Research Leidos Biomedical Research, Inc. 
Frederick, MD 21702). Whole blood was collected and centrifuged 10 minutes at 2500 rpm. 
Then, 225 μL of plasma was separated into wells along with 25 μL of treatments and incubated 
at 37 °C for 30 minutes. Two independent experiments were performed in duplicate with 
different donors. It was later performed in reading coagulometer Quick Timer II (Drake) properly 
calibrated, according to the manufacturer’s recommendations for TP Hemostasis tests (Labtest 
- Lot: 4008) and TTPA Hemostasis (Labtest - Lot: 4006). We used as reference for the TTPA 
normal value the interval between 25 and 35 seconds, while the baseline values for TP used 
the interval between 12 and 15 seconds according to the authors.9,10
 
2.3 STATISTICAL ANALYSIS
The hemolysis assay was performed in triplicate. The results were expressed as 
percentage of positive control (100%), mean ± standard deviation (S.D.). The analyzes were 
performed by variance (ANOVA) of 1-way, followed by Dunnett’s post hoc test. Values with p 
<0.05 were considered statistically significant. Coagulation was performed in two independent 
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experiments, these in duplicate with different donors. The results were expressed as mean ± 
S.D. and compared to the corresponding physiological times of each test.
3 RESULTS
The suspensions of nanocapsules produced had smooth and milky, and the white 
tone exhibited NBs and NAs exhibited slight yellowish tint due to the presence of the drug, 
which in its free form has a yellow color.
The average pH of the formulations was 6.1 and 6.3 for the NB to NA. The results 
are in accordance with the results reported by Fachinetto, Ourique, Lubini, Tedesco, Silva, 
and Beck,5 indicating that the formulations of nanocapsules produced according to pH 
have stability.
Regarding the size, the suspensions in this study showed an average diameter of 
209 nm to 218 nm for NB and NA. 
The PDI for the NB was 0.195 and for the NA of 0.158.
Figure 1 below shows the results regarding the hemolytic activity of the chemotherapeutic 
ATRA in its free form (ATRA), ATRA nanoencapsulated (NA) and blank nanocapsule (NB).
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Figure 1 – Hemolysis assay with different treatments 
Notes: Results expressed as percentage of positive control (100%). Data were expressed as mean ± 
standard deviation (SD). Analyzes were performed by 1-way ANOVA, followed by Dunnett’s post hoc 
test. Values with p <0.05 were considered statistically significant.
 The results found in the hemolytic activity of ATRA, evidenced the increase of 
the same, dependent concentration.
Performed a new v analysis and comparing free and nanocapsules concentrations 
for the presence of significant differences, as shown in Table 1 
Concentration ATRA NA “p” value
1,0 µg/mL 83,49% 65,1% <0,001
1,5 µg/mL 90% 79% <0,001
2,0 µg/mL 100% 83% <0,001
2,5 µg/mL 100% 86% <0,001
Table 1 – Comparative analysis between treatments with AL 
and NA through analysis of variance (ANOVA) of 1 
way, followed by Tukey post hoc test
These results demonstrate that although the activity of the ATRA-loaded 
nanocapsules showed haemolytic activity, still these carriers induced lower haemolytic 
toxicity compared to ATRA.
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The prothrombin time (PT) and Activated Partial Thromboplastin Time (APTT) 
were measured by measuring the coagulant activity. As previously mentioned, blood 
from healthy patients, specifically isolated plasma, was used for this study. The results 
of coagulation tests are related to the type and concentration of treatments as can be 
observed in the figures below, being TP (Figure 2) and APTT (Figure 3). Where for the 
first test, only the treatments with the nanoparticles in the concentration of 1,0 μg/mL 
remained above the physiological range. In the second test, all are within the range. Results 
greater than 1.5 μg/mL are not represented graphically by producing an anticoagulant 
effect, values greater than 120 seconds and 240 seconds, respectively.
Figure 2 – Results of PT 
Notes: The dotted boundaries correspond to expected physiological times for
healthy donors (between 12 and 15 seconds). Mean ± S.D. values from two 
independentexperiments and from different donors.
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Figure 3 – APTT results 
Notes: Dotted borders correspond to expected physiological times for healthy 
donors (between 25 and 35 seconds). Mean ± S.D. values from two independent 
experiments and from different donors.
4 DISCUSSION
Nanomedicine has evolved in the last years with the increase of the studies in 
this area. Nanoparticles increasingly play an important role in drug delivery, therapy and 
diagnosis. Because they have unique properties such as reduced size, large surface area and 
high reactivity. These characteristics make these nanoparticles have different behaviors 
according to the interaction medium.
For a particle to be considered nanometric, it is necessary that at least one of its 
dimensions is smaller than 1000 nanometers and that this causes changes in its natural 
properties. Thus, the results found for the sizes of the nanocapsules produced agree with 
the criteria established in the literature.11
The PDI measures the particle size distribution, which must be homogeneously 
distributed12 suggests that in the case of manometric particles, the formulations should be 
monodispersed, in other words, with PDI values of less than about 0.25.
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Nanoparticles may have longer systemic circulation times. These prolonged 
circulation time in the bloodstream increase the duration of contact with these blood 
components, including the coagulation system, potentially amplifying the activation of 
the coagulation cascade.13 
In APL, malignant promyelocytes reveal procoagulant substances that activate 
the coagulation cascade, usually thrombin, release fibrinogen, coagulation factors, and 
platelets. Because of this reaction, patients with APL show DIC, fibrinolysis and proteolysis.14
The fibrinolytic system is generally largely inactivated during the phase of increased 
activation of coagulation, which contributes to the deposition of fibrin. However, in some situations 
(for example, in APL) fibrinolysis may be accelerated, thus contributing to severe bleeding.15
Fibrin deposition may lead to occlusion of the vessels and consequent impairment 
of blood supply to various organs, which, together with metabolic and hemodynamic 
changes, contribute to the failure of multiple organs. Consumption and consequent 
depletion of coagulation factors and platelets resulting from continuous procoagulant 
activity may lead to diffuse bleeding, which is often the first manifestation noted. It is 
important to emphasize that the DIC is always secondary to a basic disease and the 
identification and treatment of the predisposing condition are fundamental for the 
resolution of the syndrome.16
Morbidity and mortality in APL are strongly related to coagulopathy.17 Clinically, 
APL differs from other Acute Myeloid Leukemias (AML) because it is associated with this 
alteration in about 60% to 90% of patients, the main cause of high mortality rates.12 
Hemostasis alterations were studied in 20 patients with APL prior to treatment, during 
induction of remission and after complete remission. The DIC was detected in 14 cases, 
71% of them at the time of diagnosis.17
The results found in the hemolytic activity of free ATRA, evidenced the increase of 
the same, dependent concentration, corroborating with the findings Lim, Lee and Kim.18 
ATRA in free form has poor solubility, is chemically unstable, and when exposed to different 
factors, such as light, heat and oxidants, rapidly turns into isomerized products, such as 
isotretinoin or oxidized products such as all-trans-4-oxo. ATRA is highly lipophilic and has 
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this ability to permeate phospholipid bilayers, resulting in destabilization of erythrocyte 
cell membranes.19
With these findings and reporting to the clinic of patients with APL who acquire the 
syndrome of Differentiation to the ATRA, they are found to have symptoms of medullary 
relapse and severe anemia due to the use of high doses of this chemotherapy by the vein.19
Because ATRA is a hydrophobic drug, it has low aqueous solubility, it is a major 
disadvantage to administer it intravenously. But numerous efforts have been made to allow 
its administration by this route using nanocarriers, especially lipid systems such as liposomes, 
nanoemulsions (NE) and solid lipid nanoparticles (SLN) as a drug delivery system.18
No study was found, although the activity of the nanoparticles loaded with ATRA 
had the development team, yet they induced lower haemolytic toxicity. Moreover, these 
systems present potential for accumulation of the drug through a passive targeting called 
permeability and increased retention (EPR).20
Which is a complex process, activated by fibrinogen and involving other proteins. 
It is divided into two pathways: the intrinsic (antibody-dependent) and extrinsic (non-
antibody-dependent) pathway, both ending in a common pathway.
However, the trends observed in studies of polymer-based nanoparticles, similar 
to that studied by us, are related to charge dependence as well as to hemolytic activity. 
Koziara, Oh, Akers, Ferraris, and Mumper13 showed that the reduction of the particle 
surface charge decreases platelet aggregation and activation. Previous studies have shown 
that polymeric nanoparticles injected intravenously could modify coagulation time by 
both pathways.13
Thus, the extrinsic coagulation pathway was measured using the PT test followed 
by the evaluation of the intrinsic coagulation pathway with the APTT. As previously 
mentioned, all treatments showed anticoagulants for concentrations higher than 1.5 μg/
mL for the TTPA test, in the TP test the ATRA treatment maintained the results standard 
as the previous test, but in the nanoparticle treatments the anticoagulant activity was 
observed from the concentration of 1.0 μg/mL. As the main alterations occurred in the PT 
test, it is believed that a greater interaction with the factors VII, X, V, II of coagulation and 
fibrinogen could have occurred, however, as alterations were observed in the second test 
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(APTT), we did not rule out interactions with the intrinsic factors of coagulation, among 
them, factor VIII, IX, XI, XII and protein Precalicrine.21 Other methods of analysis should be 
performed to confirm and better understand the results obtained here.
5 CONCLUSION
In conclusion of the interaction of the nanoparticles with the hemolysis tests and 
the coagulation cascade, we observed the occurrence of hemolysis with the nanoparticles 
with ATRA, but with a decrease in its toxicity compared to the free ATRA. The results for 
coagulation cascade showed that the two lowest concentrations present a safe profile, 
without intrinsic and extrinsic pathways alteration. Thus, we believe that there is a 
promising benefit to the use of these developed nanoparticles, but in vitro and in vivo 
cytogenotoxicity assays are necessary to ensure the use of these nanocarreadores aiming 
pharmacological safety of them.
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